Maryland Bids > Bid Detail

BD REAGENTS FOR COVID-19 AND HIV RESEARCH

Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Level of Government: Federal
Category:
  • 65 - Medical, Dental, and Veterinary Equipment and Supplies
Opps ID: NBD00159753513835460
Posted Date: Jan 18, 2023
Due Date: Jan 23, 2023
Solicitation No: NOI-NIAID-2157753
Source: https://sam.gov/opp/ed1568006e...
Follow
BD REAGENTS FOR COVID-19 AND HIV RESEARCH
Active
Contract Opportunity
Notice ID
NOI-NIAID-2157753
Related Notice
Department/Ind. Agency
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
NATIONAL INSTITUTES OF HEALTH
Office
NATIONAL INSTITUTES OF HEALTH NIAID
Looking for contract opportunity help?

Procurement Technical Assistance Centers (PTACs) are an official government contracting resource for small businesses. Find your local PTAC (opens in new window) for free government expertise related to contract opportunities.

General Information
  • Contract Opportunity Type: Presolicitation (Original)
  • All Dates/Times are: (UTC-05:00) EASTERN STANDARD TIME, NEW YORK, USA
  • Original Published Date: Jan 18, 2023 01:19 pm EST
  • Original Response Date: Jan 23, 2023 05:00 pm EST
  • Inactive Policy: 15 days after response date
  • Original Inactive Date:
  • Initiative:
    • None
Classification
  • Original Set Aside:
  • Product Service Code: 6505 - DRUGS AND BIOLOGICALS
  • NAICS Code:
    • 325413 - In-Vitro Diagnostic Substance Manufacturing
  • Place of Performance:
    Gaithersburg , MD 20878
    USA
Description

RE-SOLICITATION NOTICE – NOTICE OF INTENT



NOI-NIAID-2157753



NAICS – 325413



This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Becton, Dickinson and Company to procure BD brand name reagents for COVID-19 and HIV research.



The National Institutes of Health (NIH) Vaccine Research Center (VRC) is developing vaccines for SARS-CoV-2, HIV-1 and other viruses. Production of various wild-type and mutant viral proteins and anti-viral antibodies is critical in vaccine development. This requirement is for reagents for COVID-19 and HIV research. These reagents are used to examine blood and tissue derived immune cell subtypes and the cytokines they produce in animal studies where specimens have been immunized against and/or subsequently infected with COVID-19 OR SHIV (the non-human primate equivalent of human immunodeficiency virus). The reagents required on this acquisition have been selected based on their continued use in a qualified assay that relies on stringent reproducibility across experiments and users. The reagents have been titrated to ensure correct amount per assay, as well as the specific clone or isotype that yields the most consistent results. Deviation from these qualified reagents will require substantial person-hours to recertify new reagents and will also forfeit consistency with previous studies related to the ongoing research. Development of panels for immunophenotyping by high-dimensional flow cytometry requires extensive and sophisticated testing of reagents. The VRC has tested several of these reagents from different companies and selected the best performing reagents. Often, the selection of reagents differs among vendors and many fluorochromes and reagents are only available from BD Biosciences. Based on these facts must obtain these reagents from BD Biosciences.



The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the following Becton, Dickinson & Co (BD Biosciences) Brand Name Supplies:



560493 Hu IL-21 Alexa 647 3A3-N2.1 100Tst QTY 20 EA



563580 Hu IL-13 BV421 JES10-5A2 50Tst QTY 50 EA



566361 Hu IL-2 BV750 MQ1-17H12 50ug QTY 30 EA



554512 Hu TNF FITC MAb11 100ug Flow Assay QTY 30 EA



Shipping and Handling



Place of Performance: NIH, 9 West Watkins Mill Road, Gaithersburg, MD 20878, United States. FOB: Destination



The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2157753 to Dana Monroe at dana.monroe@nih.gov by 5:00pm EST January 23, 2023. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.


Attachments/Links
Contact Information
Contracting Office Address
  • 5601 FISHERS LANE, SUITE 3D11
  • BETHESDA , MD 20892
  • USA
Primary Point of Contact
Secondary Point of Contact


History
  • Jan 18, 2023 01:19 pm ESTPresolicitation (Original)

TRY FOR FREE

Not a USAOPPS Member Yet?

Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.

Start Free Trial Today >